Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05658029 | May → Sep 2023 | tracheal disorder | Matthew Bruehl | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02324426 | Dec 2014 → Mar 2015 | Parkinson disease | University of Washington | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05495243 | Oct 2022 → Feb 2024 | bronchiectasis | Renovion, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05654922 | Apr 2023 → May 2026 overdue | bronchiolitis obliterans syndrome | Renovion, Inc. | Recruiting | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 1/2 | NCT02651350 Background | Dec 2015 → Jul 2019 | drug-induced liver injury | Beijing 302 Hospital | Completed | Met primary |
| Phase 1/2 | NCT01844063 Background | Jul 2013 → Jan 2016 | liver failure | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT02424708 Comparator | Apr 2015 → Mar 2016 | Parkinson disease | Bastyr University | Completed | No outcome recorded |
| Phase 2 | NCT00266331 Comparator | Oct 2004 → May 2011 | breast cancer | Nathalie Johnson | Completed | No outcome recorded |
| Phase 4 | NCT04906083 Background | Feb 2021 → Dec 2022 | cirrhosis of liver, liver failure, thrombocytopenia | Tongji Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02331745 Background | Oct 2013 → Apr 2016 | alcoholic liver disease, hepatitis B virus infection, liver failure | Beijing 302 Hospital | Unknown | No outcome recorded |
| — | NCT01344174 Background | May → Aug 2011 | hepatitis B virus infection, liver failure | Third Military Medical University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | reduced glutathione | “Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission.” NCT02331745 ↗10“B.Hepatoprotective drugs(Ademetionine1,4-butanethiosulfonate for Injection, Reduced Glutathione for Injection,Polyene Phosphatidylcholine, et al)” NCT01844063 ↗ “Standard medical treatment included transmetil, compound glycyrrhizinate, reduced glutathione and hepatocyte growth factor, et. al.” NCT04906083 ↗ “Fixed-dose solution of ascorbic acid and reduced glutathione nebulized twice daily for 4 weeks (28 days)” NCT05658029 ↗ “Transfusion of magnesium glycyrrhizinate injection (200mg, 1/d) and reduced glutathione (1200mg, 1/d);” NCT01344174 ↗ “including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA)” NCT02651350 ↗ “ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)” NCT05654922 ↗ “ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)” NCT05495243 ↗ |
| Known as | Glutathione | “Phase IIb Study of Intranasal Glutathione in Parkinson's Disease” NCT02424708 ↗ |
| Known as | GSH | “The study medication is packaged in sterile 1 ml pre-filled syringes, each containing 200 mg/ ml of reduced glutathione (GSH), which will be delivered intranasally.” NCT02324426 ↗2“ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)” NCT05654922 ↗ “ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)” NCT05495243 ↗ |
| Route | Intranasal | “which will be delivered intranasally” NCT02324426 ↗ |